A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors
Phase 1
Recruiting
- Conditions
- Squamous Cell Carcinoma of Head and NeckUrothelial CarcinomaEndometrial CancerHR+/HER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Totus Medicines
- Target Recruit Count
- 241
- Registration Number
- NCT05683418
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath